Ticker Details
Esperion Therapeutics, Inc. Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.
IPO Date:	June 26, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$831.94M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.73 | 3.26%
Avg Daily Range (30 D):	$0.10 | 2.94%
Avg Daily Range (90 D):	$0.11 | 3.21%

Institutional Daily Volume
Avg Daily Volume:	1.72M
Avg Daily Volume (30 D):	4.28M
Avg Daily Volume (90 D):	5.02M

Trade Size
Avg Trade Size (Sh.):	219
Avg Trade Size (Sh.) (30 D):	280
Avg Trade Size (Sh.) (90 D):	298

Institutional Trades
Total Institutional Trades:	3,152
Avg Institutional Trade:	$1.78M
Avg Institutional Trade (30 D):	$1.11M
Avg Institutional Trade (90 D):	$1.31M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.21M
Avg Closing Trade (30 D):	$.93M
Avg Closing Trade (90 D):	$1.28M
Avg Closing Volume:	125.28K

News

Feb 17, 2026 @ 1:00 PM Esperion Reaches Settlement Agreement with Fifth A... Source: Na

Nov 21, 2025 @ 1:00 PM Esperion Partner Otsuka Launches NEXLETOL® in J... Source: Sheldon Koenig

Nov 18, 2025 @ 12:00 PM Esperion Partner HLS Therapeutics Announces Approv... Source: Esperion

Nov 4, 2025 @ 1:00 PM Esperion Appoints Industry Veteran John Harlow as ... Source: Esperion Therapeutics

Oct 27, 2025 @ 12:00 PM Esperion Announces New Analyses from CLEAR Outcome... Source: Esperion Therapeutics

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.54	$-.16
Diluted EPS	$-.54	$-.16
Revenue	$303.8M	$87.31M
Gross Profit
Net Income / Loss	$-105.83M	$-31.33M	$-12.73M
Operating Income / Loss	$-29.38M	$-9.96M
Cost of Revenue
Net Cash Flow	$.04M
PE Ratio

Splits
Jun 11, 2013	1:7